Orphazyme completes enrollment in phase 3 trial evaluating arimoclomol in Amyotrophic Lateral Sclerosis
18 juil. 2019 01h00 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 17/2019 ...
Orphazyme to prepare for filing of arimoclomol in Europe for Niemann-Pick disease Type C (NPC)
07 juin 2019 00h56 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Orphazyme’s Phase II/III trial in sporadic Inclusion Body Myositis fully enrolled
23 avr. 2019 06h39 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 13/2019 ...
Publication of manuscript on preclinical Proof-of-Concept of arimoclomol in Gaucher disease
27 nov. 2018 08h51 HE
|
ORPHAZYME A/S
Orphazyme A/SInvestor news No....
Orphazyme reports encouraging arimoclomol clinical trial top-line data in Niemann-Pick disease Type C (NPC)
28 sept. 2018 01h00 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Orphazyme to Present at 25th NPUK Annual Family Conference 2018
20 sept. 2018 09h19 HE
|
ORPHAZYME A/S
Orphazyme A/SInvestor news No....
Orphazyme announces enrollment of first patient in Phase III clinical trial of arimoclomol for ALS
10 août 2018 12h19 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Publication of manuscript related to Phase II trial results for arimoclomol in patients with SOD1 ALS
24 janv. 2018 16h06 HE
|
ORPHAZYME A/S
Investor newsOrphazyme A/SNo. 01/2018 ...